Home › Law Database › Indonesia

Are peptides legal in Indonesia?

Sourced guide to the legal status of peptides in Indonesia, refreshed automatically from live research.

Overall Status: Gray Area

Short answer: Peptides such as BPC-157 and TB-500 are not legally sold as approved medicines in Indonesia and fall into a regulatory gray zone as unregistered, unapproved substances, while pharmaceutical peptides like semaglutide are prescription-only medicines regulated by Indonesia's national drug agency, BPOM.

Important: This information is for educational purposes only and does not constitute legal advice. Laws and enforcement policies change. Consult a qualified attorney for specific legal guidance.

Overview

Peptides in Indonesia are not covered by a single, peptide-specific law; instead they fall under Indonesia's general medicines framework administered by BPOM (Badan Pengawas Obat dan Makanan), the national Food and Drug Authority. Peptide-based pharmaceutical products with marketing authorization, such as GLP-1 diabetes and weight-loss drugs, are classified as prescription ('obat keras') medicines that must be dispensed by licensed pharmacies. Research-grade peptides like BPC-157 and TB-500 have no Indonesian marketing authorization, meaning they cannot be lawfully sold as drugs or supplements for human use, leaving their sale largely confined to an unregulated online/research-chemical gray market. No Indonesia-specific statute, regulation, or BPOM public warning naming BPC-157, TB-500, or 'research peptides' by name was found in this research session.

Key Points

  • Indonesia has no publicly identified peptide-specific statute; peptides are instead governed by BPOM's general drug-registration and prescription-medicine framework, and no primary source naming peptides specifically could be verified in this research session. (No reliable source found for this point -- flagged as unverified rather than stated as fact.)
  • Pharmaceutical peptides with BPOM marketing authorization (izin edar), such as semaglutide-class GLP-1 products, are classified as prescription-only ('obat keras') medicines in Indonesia and must be dispensed through a licensed pharmacy with a doctor's prescription, based on Indonesia's general prescription-medicine classification system. (No reliable source found for this point -- flagged as unverified rather than stated as fact.)
  • Research-grade peptides such as BPC-157 and TB-500 do not hold BPOM marketing authorization in Indonesia, meaning no Indonesian regulator has approved them as safe or effective drugs for human use. (No reliable source found for this point -- flagged as unverified rather than stated as fact.)
  • Personal importation of unregistered injectable peptides into Indonesia is legally risky because Indonesian customs and BPOM rules generally restrict bringing unregistered medicines/pharmaceutical products into the country without prior BPOM import approval, though a specific peptide-focused customs ruling could not be verified in this research session. (No reliable source found for this point -- flagged as unverified rather than stated as fact.)
  • No BPOM public warning, circular, or enforcement action specifically naming 'peptides,' BPC-157, TB-500, or research-chemical peptide sellers was located during this research session, so the extent of active Indonesian enforcement against this category remains unconfirmed from primary sources. (No reliable source found for this point -- flagged as unverified rather than stated as fact.)
  • Internationally, BPC-157 is treated by regulators such as the U.S. Department of Defense's Operation Supplement Safety as a prohibited, unapproved peptide drug found in wellness products, illustrating a global regulatory pattern of non-approval that Indonesia's framework, requiring BPOM registration for any legally marketed drug, is broadly consistent with. [1]
  • No recent (2023-2026) Indonesian bill, regulation amendment, or BPOM policy update specifically addressing peptides or research chemicals was found in this research session. (No reliable source found for this point -- flagged as unverified rather than stated as fact.)

Peptide-by-peptide status in Indonesia

BPC-157BPC-157 has no BPOM-approved drug status in Indonesia and is not a legally registered medicine there, placing it in the same unapproved category internationally recognized by bodies like the U.S. Department of Defense's supplement-safety program. [1]
Semaglutide / Tirzepatide (GLP-1 class)Semaglutide and tirzepatide products approved for diabetes or weight loss are prescription-only ('obat keras') medicines in Indonesia that require a doctor's prescription and BPOM marketing authorization to be legally dispensed, based on Indonesia's general prescription-drug framework; no specific BPOM registration document could be verified in this session.
TB-500 (Thymosin Beta-4)TB-500 has no confirmed BPOM marketing authorization in Indonesia, and no Indonesia-specific regulatory statement on this compound could be located during this research session.
Human Growth Hormone (HGH/Somatropin)Somatropin (HGH) is generally treated as a prescription-only hormone medicine in Indonesia's broader pharmaceutical framework, but no Indonesia-specific BPOM document confirming its exact scheduling could be verified in this research session.

Sources

Last researched: 2026-09-10

Frequently asked questions

Can I buy peptides like BPC-157 in Indonesia without a prescription?
Legally marketed, BPOM-approved peptide medicines cannot be bought without a prescription in Indonesia, and research peptides like BPC-157 have no BPOM approval at all, so any purchase of BPC-157 in Indonesia occurs outside the regulated pharmaceutical system.
Can I bring peptides into Indonesia when traveling?
Bringing unregistered injectable peptides into Indonesia carries legal risk because medicines generally need BPOM registration or import clearance to enter the country lawfully, though a peptide-specific customs ruling could not be confirmed in this research session.
Can a doctor prescribe peptides like semaglutide via telehealth in Indonesia?
Prescription peptide medicines such as semaglutide would need to follow Indonesia's general telehealth and prescribing rules administered by the Ministry of Health, but no specific Indonesian telehealth-peptide guidance was found in this research session.
What happens if I sell unregistered research peptides in Indonesia?
Selling unregistered pharmaceutical products in Indonesia without BPOM authorization would generally fall under Indonesia's broader medicine-control enforcement framework, but no specific BPOM enforcement case against peptide sellers was located during this research session.
Is BPC-157 considered a legal supplement in Indonesia?
BPC-157 is not a BPOM-approved supplement or drug in Indonesia, mirroring its treatment elsewhere as an unapproved peptide drug rather than a lawful dietary supplement. [1]